Compare Immunovant Inc. Common Stock (IMVT) vs JPMorgan Equity Premium Income ETF (JEPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs JPMorgan Equity Premium Income ETF — how do they compare? Immunovant Inc. Common Stock trades at $30.27 (market cap $6.25B), while JPMorgan Equity Premium Income ETF trades at $56.72 (market cap $45.55B). The key difference: JPMorgan Equity Premium Income ETF is far larger — about 7.3× Immunovant Inc. Common Stock's market cap, and Immunovant Inc. Common Stock is trading nearer its 52-week high, JPMorgan Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and JPMorgan Equity Premium Income ETF for 56 Days on average.
| IMVT | JEPI | |
|---|---|---|
Market Cap | $6.25B | $45.55B |
Volume | 1,755,411 | 3,820,809 |
Sector | Health | Income / Options Overlay |
52-Week High | $44.96 | $59.88 |
52-Week Low | $17.03 | $55.29 |
Typical Hold Time | 0 Days | 56 Days |
Enterprise Value | $5.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
JEPI trades at $56.45, down 0.16% with a bearish technical outlook. The ETF maintains consistent monthly dividend distributions, with recent payments of $0.37 in August and September 2026. Technical indicators show bearish momentum with selling pressure in moving averages, while oscillators remain neutral. The fund continues to attract income-focused investors seeking monthly payouts through its covered call strategy.
The outlook remains cautious given the bearish technical signals and market volatility. Income investors may find value in the consistent dividend stream, but capital appreciation potential appears limited in the current technical environment. Key risks include market direction sensitivity and interest rate impacts on income strategies.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About JPMorgan Equity Premium Income ETF
JEPI is an actively managed ETF that seeks to deliver monthly income and stock market exposure with lower volatility. It combines an equity portfolio with an options strategy to generate steady premiums.
Read more on JEPI →
